Infliximab, adalimumab nearly tied for pediatric IBD infection risk

Infliximab and adalimumab exhibited similar infection risk profiles in children and adolescents with inflammatory bowel disease when used as initial biologic therapy, according to study results published in JAMA Network Open.
Researchers reported that serious infections were “rare” with use of either biologic, with slightly higher rates of outpatient infections.
“Infliximab and adalimumab are the only biologic therapies approved by the FDA for both Crohn’s disease and ulcerative colitis in children, and both are commonly used as initial biologic treatments,” Ning Lyu, PhD, MS, a postdoctoral

Social determinants can determine outcomes in rheumatology care

FORT LAUDERDALE, Fla. — Social determinants of health contribute to significant disparities in rheumatology care, according to a presenter at the Rheumatology Nurses Society annual conference.
“We are so much more than our diagnosis or disease,” Nayimisha Balmuri, MD, MS, MSE, FAAP, FACR, assistant professor in clinical pediatrics in the Eudowood division of allergy, immunology and rheumatology at the Johns Hopkins School of Medicine, told attendees. “There are patients that no matter what you prescribe, they always come back with active disease.”
Social